Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
McKesson
Harvard Business School
Mallinckrodt
AstraZeneca

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Linezolid In Sodium Chloride 0.9% In Plastic Container, and what generic alternatives are available?

Linezolid In Sodium Chloride 0.9% In Plastic Container is a drug marketed by Hospira Inc and is included in one NDA.

The generic ingredient in LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is linezolid. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the linezolid profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Linezolid In Sodium Chloride 0.9% In Plastic Container

A generic version of LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER was approved as linezolid by TEVA PHARMS on June 27th, 2012.

  Free Forever Trial

Summary for LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Drug patent expirations by year for LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Recent Clinical Trials for LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
De La Salle Health Sciences Institute, PhilippinesPhase 2
University of Colorado, DenverPhase 2
Otsuka Pharmaceutical Co., Ltd.Phase 2

See all LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER clinical trials

Pharmacology for LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Anatomical Therapeutic Chemical (ATC) Classes for LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

US Patents and Regulatory Information for LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira Inc LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER linezolid SOLUTION;INTRAVENOUS 206473-001 Jun 18, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
AstraZeneca
Baxter
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.